Table 2.
Sample | VZV 63,a copies/ml | VZV 21,b copies/ml | VZV 31,c copies/ml |
---|---|---|---|
MS 1 | 0 | 0 | 0 |
MS 2 | Traced | 0 | 0 |
MS 3 | 0 | 0 | 0 |
MS 4 | 0 | 0 | 0 |
MS 08-1 (remission) | 0 | 0 | 0 |
CIS 1 | 0 | 0 | 0 |
CIS 2 | Traced | 0 | 0 |
CIS 3 | Traced | 0 | 0 |
MS 95-A3 acute plaque | 0 | ND | ND |
MS 03-A1 acute plaque | 0 | ND | ND |
OIND 06-1 SSPE | 0 | 0 | 0 |
OIND 08-1 VZV vasculopathy | 0 | 0 | 0 |
OIND 08-5 VZV radiculomyelitis | 8,000 | 14,200 | 9,710 |
OIND 04-5 cryptococcal meningitis | Traced | 0 | 0 |
OIND 05-1 neurosyphilis | 0 | 0 | 0 |
OIND 05-2 chronic meningitis | Traced | 0 | 0 |
OIND VZV culture supernatant | 6.989 E6 | 18.7 E6 | 291,500 |
Open reading frames (ORF) 63 primers sensitive to detect 10 copies varicella zoster virus (VZV) DNA.
ORF 21 primers sensitive to detect 400 copies VZV DNA.
ORF 31 primers sensitive to detect 40 copies VZV DNA.
Trace: amplification at 40 cycles (between 1 and 10 copies) is below the lower limit of reliability for the standard curve with VZV ORF 63 primers.
MS = multiple sclerosis; CIS = clinically isolated syndrome; ND = not done; OIND = other inflammatory neurological disease; SSPE = subacute sclerosing panencephalitis.